Kuhr Christian S, Lupu Marilena, Little Marie-Térèse, Zellmer Eustacia, Sale George E, Storb Rainer
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Transplantation. 2006 May 27;81(10):1460-2. doi: 10.1097/01.tp.0000203323.82681.7d.
Graft-versus-host disease (GVHD) remains a cause of substantial morbidity for patients undergoing allogeneic hematopoietic cell transplantation (HCT). The present study was undertaken to investigate the effectiveness of RDP58, a peptide derived from the human leukocyte antigen class I heavy chain, in preventing GVHD in the established dog leukocyte antigen (DLA)-nonidentical canine model. Dogs underwent HCT from unrelated DLA-nonidentical donors after conditioning with 920 cGy total body irradiation. Engraftment and achievement of full donor chimerism was seen in five of six dogs, whereas one dog showed rejection and died of marrow aplasia. All five dogs with engraftment developed acute GVHD and were euthanized at an average of 20.6 days after HCT. Compared with historical controls, the Suse of RDP58 neither prevented acute GVHD nor significantly prolonged survival of DLA-nonidentical HCT recipients.
移植物抗宿主病（GVHD）仍然是接受异基因造血细胞移植（HCT）患者出现严重发病情况的一个原因。本研究旨在调查RDP58（一种源自人类白细胞抗原I类重链的肽）在已建立的犬白细胞抗原（DLA）不匹配犬模型中预防GVHD的有效性。在用920 cGy全身照射进行预处理后，犬接受来自不相关DLA不匹配供体的HCT。六只犬中有五只出现植入并实现完全供体嵌合，而一只犬出现排斥反应并死于骨髓再生障碍。所有五只植入的犬均发生急性GVHD，并在HCT后平均20.6天实施安乐死。与历史对照相比，使用RDP58既不能预防急性GVHD，也不能显著延长DLA不匹配HCT受者的生存期。
